Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Novel <i>SZT2::MAST2</i> Fusion Detected in Salivary Duct Carcinoma.

Case reports in pathology·2025

Same author

Novel <i>MAML2</i> Fusions in Human Malignancy.

Cancers·2025

Same author

BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.

Genes, chromosomes & cancer·2025

Same author

Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.

Leukemia & lymphoma·2025

Same author

Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.

Cancer research communications·2025

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation.

Mark G Evans¹, Sherif A Rezk², Lauren C Pinter-Brown³

¹Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Case Reports in Hematology

|October 25, 2021

Summary

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is rare and can present with leukemic features and CD5 expression. This case highlights the aggressive clinical course and poor prognosis associated with this rare lymphoma subtype.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Related Experiment Videos

Last Updated: Oct 15, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Area of Science:

Hematology
Oncology
Immunology

Background:

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin lymphoma.
A subset of DLBCL cases exhibit CD5 expression, but its prognostic significance is unclear.

Observation:

A 78-year-old male presented with circulating lymphoma cells in peripheral blood and bone marrow involvement.
The lymphoma was identified as diffuse large B-cell lymphoma, germinal center B-cell subtype, with CD5 expression.

Findings:

The patient achieved a favorable initial response to etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) chemotherapy and intrathecal methotrexate.
Despite initial treatment, the patient relapsed with lymphadenopathy and ultimately succumbed to the disease approximately one year post-diagnosis.

Implications:

This case underscores the aggressive nature of CD5-positive primary bone marrow DLBCL.
Further research is warranted to elucidate the prognostic impact of CD5 expression in this rare lymphoma entity.